GMAB vs REGN vs INCY vs ABBV vs PFE

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus -82. 7% for Genmab A/S (GMAB). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus AbbVie Inc. at 85. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Genmab A/S wins at 0. 80x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -27. 6% for Genmab A/S (GMAB). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus PFE's +29. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Genmab A/S's 0. 92β — meaning GMAB is approximately 171% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 93% for Genmab A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus -82. 7% for Genmab A/S (GMAB). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -87. 3% for Genmab A/S. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 33. 6% versus 24. 7% for PFE. At the gross margin level — before operating expenses — GMAB leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Genmab A/S (GMAB) is the more undervalued stock at a PEG of 0. 80x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 23. 3x for Genmab A/S — 14. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 47. 5% to $39. 90.

In this comparison, PFE (6.

5% yield), ABBV (3. 2% yield), REGN (0. 5% yield) pay a dividend. GMAB, INCY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, GMAB: +74. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap deep-value stock; REGN is a mid-cap deep-value stock; INCY is a mid-cap high-growth stock; ABBV is a large-cap income-oriented stock; PFE is a mid-cap income-oriented stock. ABBV, PFE pay a dividend while GMAB, REGN, INCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.